{"id":"W2968495081","doi":"10.1634/theoncologist.2019-0297","title":"Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with<i>RAS/RAF</i>Alterations","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; Array BioPharma","keywords":"KRAS; Medicine; Neuroblastoma RAS viral oncogene homolog; MEK inhibitor; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Toxicity; Phases of clinical research; Pharmacology; Colorectal cancer; MAPK/ERK pathway; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001590649,0.001611224,0.002366509,0.0005057633,0.0004679829,0.001151711,0.001098074,0.0008370091,0.003441214],"category_scores_gemma":[0.0007266765,0.0007288622,0.001253502,0.0005357849,0.0008820889,0.0009679574,0.0004771295,0.003246812,0.001077957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001047907,"about_ca_system_score_gemma":0.001909675,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000701395,"about_ca_topic_score_gemma":0.001513051,"domain_scores_codex":[0.9994148,0.0002506482,0.0000405614,0.0001000536,0.00006741861,0.0001266192],"domain_scores_gemma":[0.9990569,0.0001094775,0.0002148975,0.00008301441,0.00006138584,0.000474413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7276503,0.1165405,0.01072086,0.0007494814,0.001897887,0.0003337723,0.0003199617,0.003078721,0.06230818,0.000241618,0.002945838,0.07321282],"study_design_scores_gemma":[0.4521212,0.5305588,0.008417297,0.00003184923,0.0004754553,0.0004219356,0.0000508534,0.001258387,0.004613877,0.0001188429,0.001905326,0.00002617319],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933382,0.001553259,0.0005973392,0.0002892774,0.00007773946,0.00190754,0.0006846186,0.00007512145,0.001477011],"genre_scores_gemma":[0.9914894,0.001054664,0.001627266,0.0004816699,0.0001335981,0.002044421,0.00200431,0.00002924535,0.001135531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003441214,"threshold_uncertainty_score":0.01151198,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009872657720289805,"score_gpt":0.3163407426654571,"score_spread":0.3064680849451673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}